Search
Submit an article RU
Advanced targets in Biomedicine

Current issue

Back to the list Download the article
ENG
Сохранить XML для: JATS (вып.)
Gorokhova A. V. Nasibov T. F. Ryzhkova A. Yu. Leshenkova A. V. Porokhova E. D. Dzyuman A. N. Avdeeva E. Yu. Belousov M. V. Khlusov I. A.

The effect of naturally occurring chelidonic acid on the morphofunctional status of internal organs: an experimental study

DOI
10.5922/ATB-2026-2-1-7
Pages
101-123
To cite
Gorokhova A. V., Nasibov T. F., Ryzhkova A. Yu., Leshenkova A. V., Porokhova E. D., Dzyuman A. N., Avdeeva E. Yu., Belousov M. V., Khlusov I. A. The effect of naturally occurring chelidonic acid on the morphofunctional status of internal organs: an experimental study. Advanced targets in Biomedicine. 2026;2(1):101—123. https://doi.org/10.5922/ATB-2026-2-1-7
Saussurea controversa chelidonic acid oral admi­nistration stomach liver kidneys spleen morphometric ana­lysis

Abstract

For the first time, a comprehensive in vivo evaluation of the effects of long-term (45 days) daily intragastric administration of water solution of naturally occurring small molecules of chelidonic acid (ChA) to Balb/c mice was conducted. The study was focused on the morphofunctional state of several key organs involved in xenobiotic metabolism and excretion, including the stomach, liver, kidneys, as well as an immunocompetent organ (spleen). The obtained results demonstrate the absence of pathological changes in these organs when the substance was administered orally at a concentration of 10 mg/ kg in 0.2 ml of solvent (distilled water) for 45 days. Moreover, as previously established, ChA and its calcium salt at the indicated dose exhibit specific (osteogenic) activity against mesenchymal stromal/stem cells both in vitro and in vivo. These findings indicate an absence of general toxicity to studied organs of a low concentration of ChA in lineage mice, suggesting that it may be a promising candidate for future clinical use. This opens up promising opportunities for further research and development of an active pharmaceutical substance that is entirely domestic in origin. This is of great importance for the advancement of the field of regenerative biomedicine, primarily in the area of bone tissue engineering.

Reference

  1. Mitchell J., Lo K. W. H. Small molecule-mediated regenerative engineering for craniofacial and dentoalveolar bone. Front. Bioeng. Biotechnol. 2022, 10, 1003936, DOI: 10.3389/fbioe.2022.1003936.
  2. Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 2001, 46(1—3), 3—26, DOI: 10.1016/s0169-409x(00)00129-0.
  3. Scott D. E., Bayly A. R., Abell C., Skidmore J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug. Discov. 2016, 15(8), 533—550, DOI: 10.1038/nrd.2016.29.
  4. Chen S., Song Z., Zhang A. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. Curr. Top. Med. Chem. 2019, 19(3), 180—185, DOI: 10.2174/1568026619666190308131805.
  5. Toogood P. L. Small molecule immuno-oncology therapeutic agents. Bioorg. Med. Chem. Lett. 2018, 28(3), 319—329, DOI: 10.1016/j.bmcl.2017.12.044.
  6. Morgan S., Grootendorst P., Lexchin J., Cunningham C., Greyson D. The cost of drug development: a systematic review. Health Policy. 2011, 100(1), 4—17, DOI: 10.1016/j.healthpol.2010.12.002.
  7. Newman D. J., Cragg G. M. Natural Products as Sources of New Drugs over the Nearly Four De­cades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83(3), 770—803, DOI: 10.1021/acs.jnatprod.9b01285.
  8. Nielsen H. M., Jorgensen L. Challenges in Delivery of Biopharmaceuticals; the Need for Advanced Delivery Systems. Delivery Technologies for Biopharmaceuticals, John Wiley & Sons, Ltd; 2009. 1—8, DOI: 10.1002/9780470688397.ch1.
  9. Makurvet F. D. Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery. 2021, 9, 100075, DOI: 10.1016/j.medidd.2020.100075.
  10. Miroshnichenko L. A., Polyakova T. Y., Avdeeva E. Y., Krivoshchekov S. V., Khlu­sov I. A., Belousov M. V. Chelidonic Acid and its Derivates: General Spectrum of Biological Activity and Osteogenic Properties (Review). Drug development & registration. 2022, 11(4), 60—71, DOI: 10.33380/2305-2066-2022-11-4-60-71.
  11. Kim D.-S., Kim S.-J., Kim M.-C., Jeon Y.-D., Um J., Hong S.-H. The therapeutic effect of chelidonic acid on ulcerative colitis. Biol. Pharm. Bull. 2012, 35(5), 666—671, DOI: 10.1248/bpb.35.666.
  12. Liu H., Zheng Y., Li C., Zheng Y., Wang D., Wu Z., et al. Discovery of Anti-inflammatory Ingredients in Chinese Herbal Formula Kouyanqing Granule based on Relevance Analysis between Chemical Characters and Biological Effects. Sci. Rep. 2015, 5, 18080, DOI: 10.1038/srep18080.
  13. Oh H.-A., Kim H.-M., Jeong H.-J. Beneficial effects of chelidonic acid on a model of allergic rhinitis. Int. Immunopharmacol. 2011, 11(1), 39—45, DOI: 10.1016/j.intimp.2010.10.002.
  14. Singh D. K., Gulati K., Ray A. Effects of chelidonic acid, a secondary plant metabolite, on mast cell degranulation and adaptive immunity in rats. Int. Immunopharmacol. 2016, 40, 229—234, DOI: 10.1016/j.intimp.2016.08.009.
  15. Aytemir M. D., Uzbay T., Erol D. D. New 4(1H)-pyridinone derivatives as analgesic agents. Arzneimittelforschung. 1999, 49(3), 250—254, DOI: 10.1055/s-0031-1300409.
  16. Oztürk G., Erol D. D., Aytemir M. D., Uzbay T. New analgesic and antiinflammatory agents 4(1H)-pyridinone derivatives. Eur. J. Med. Chem. 2002, 37(10), 829—834, DOI: 10.1016/s0223-5234(02)01390-9.
  17. Jeong H.-J., Yang S.-Y., Kim H.-Y., Kim N.-R., Jang J.-B., Kim H.-M. Chelidonic acid evokes antidepressant-like effect through the up-regulation of BDNF in forced swimming test. Exp. Biol. Med. (Maywood). 2016, 241(14), 1559—1567, DOI: 10.1177/1535370216642044.
  18. Hamada Y., Suzuki K., Nakanishi T., Sarma D., Ohta H., Yamaguchi R., et al. Structure-activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P(2) position. Bioorg. Med. Chem. Lett. 2014, 24(2), 618—623, DOI: 10.1016/j.bmcl.2013.12.007.
  19. Porter T. G., Martin D. L. Chelidonic acid and other conformationally restricted substrate analogues as inhibitors of rat brain glutamate decarboxylase. Biochem. Pharmacol. 1985, 34(23), 4145—4150, DOI: 10.1016/0006-2952(85)90207-2.
  20. Avdeeva E., Shults E., Rybalova T., Reshetov Y., Porokhova E., Sukhodolo I., et al. Chelidonic Acid and Its Derivatives from Saussurea Controversa: Isolation, Structural Elucidation and Influence on the Osteogenic Differentiation of Multipotent Mesenchymal Stromal Cells In vitro. Biomolecules. 2019, 9(5), 189, DOI: 10.3390/biom9050189.
  21. Avdeeva E., Porokhova E., Khlusov I., Rybalova T., Shults E., Litvinova L., et al. Calcium Chelidonate: Semi-Synthesis, Crystallography, and Osteoinductive Activity In vitro and In vivo. Pharmaceuticals (Basel). 2021, 14(6), 579, DOI: 10.3390/ph14060579.
  22. Nasibov T., Gorokhova A., Starosvetskaya A., Bariev U., Nosov V., Litvinova L., et al. In situ and in silico modeling of the hematopoiesis-inducing effect of chelidonic acid. Russ. J. Immunol. 2024, 27(2), 187—196, DOI: 10.46235/1028-7221-16768-ISA.
  23. Nasibov T., Gorokhova A., Porokhova E., Shupletsova V., Yurova K., Avdeeva E., et al. A hypothesis of mesenchymal stem cell osteogenic differentiation mediated by chelidonic acid through the calcium import: original research and computer simulation. Histochem. Cell Biol. 2024, 163(1), 14, DOI: 10.1007/s00418-024-02342-5.
  24. Nasibov T. F., Gorokhova A. V., Brazovsky K. S., Porokhova E. D., Avdeeva E. Y., Be­lousov M. V., et al. The pipeline for in silico prediction of target genes and target metabolic pathways for small molecules, using chelidonic acid as an example. Adv. Target Biomed. 2025, 1(1), 6—19, DOI: 10.5922/ATB-2025-1-1-1.
  25. Pearse A. G. E. Histochemistry, Theoretical and Applied. London: Churchill Livingstone, 1968. 759.
  26. Shakhov V. P., Khlusov I. A., Dambaev K. V., Zaitsev K. V., Salmina A. B., Shakhova S. S. et al. Introduction to methods of cell culture, bio-engineering of organs and tissues. Tomsk: STT, 2004. 385.
  27. Royston P. Remark AS R94: a remark on algorithm AS 181: the W-test for normality. J. R. Stat. Soc. Ser. C Appl. Stat. 1995, 44(4), 547–551, DOI: 10.2307/2986146.
  28. Celik N. Welch’s ANOVA: Heteroskedastic skew-t error terms: Communications in Statistics. Theory and Methods. 2022, 51(9), 3065—3076, DOI: 10.1080/03610926.2020.1788084.
  29. Delacre M., Lakens D., Leys C. Why Psychologists Should by Default Use Welch’s t-test Instead of Student’s t-test. International Review of Social Psychology. 2017, 30(1), 92, DOI: 10.5334/irsp.82.
  30. Tomarken A. J., Serlin R. C. Comparison of ANOVA alternatives under variance he­terogeneity and specific noncentrality structures. Psychol. Bull. 1986, 99(1), 90—99, DOI: 10.1037/0033-2909.99.1.90.
  31. Levy K. J. An empirical comparison of the ANOVA F-test with alternatives which are more robust against heterogeneity of variance. J. Stat. Comput. Sim. 1978, 8(1), 49—57, DOI: 10.1080/00949657808810247.
  32. Lix L. M., Keselman J. C., Keselman H. J. Consequences of Assumption Violations Revisited: A Quantitative Review of Alternatives to the One-Way Analysis of Variance F Test. Review of Educational Research. 1996, 66(4), 579—619, DOI: 10.3102/00346543066004579.
  33. Tamhane A. C. A Comparison of Procedures for Multiple Comparisons of Means with Unequal Variances. J. Am. Stat. Assoc. 1979, 74(367), 471—480, DOI: 10.1080/01621459.1979.10482541.
  34. Elamir E. On uses of van der Waerden test: a graphical approach. 2022. Available from: arXiv: 2203.02148, DOI: 10.48550/arXiv.2203.02148.
  35. Macunluoglu A. C., Ocakoğlu G. Comparison of the performances of non-parametric k-sample test procedures as an alternative to one-way analysis of variance. Eur. Res. J. 2023, 9, 687—696, DOI: 10.18621/eurj.1037546.
  36. Luepsen H. Comparison of nonparametric analysis of variance methods: a Monte Carlo study — a vote for van der Waerden. Commun. Stat. Simul. Comput. 2018, 47(9), 2547—2576, DOI: 10.1080/03610918.2017.1353613.
  37. Douglas C. E., Michael F. A. On distribution-free multiple comparisons in the one-way analysis of variance. Communications in Statistics - Theory and Methods. 1991, 20(1), 127—139, DOI: 10.1080/03610929108830487.
  38. Miller R. G. Nonparametric Techniques. In: Miller RG, editor. Simultaneous Statistical Infe­rence, N Y: Springer, 1981. 129—188, DOI: 10.1007/978-1-4613-8122-8_4.
  39. Madra S., Styles J., Smith A. G. Perturbation of hepatocyte nuclear populations induced by iron and polychlori­nated biphenyls in C57BL/10ScSn mice during carcinogenesis. Carcinogenesis. 1995, 16(4), 719—727, DOI: 10.1093/carcin/16.4.719.
  40. Jácome F. C., Caldas G. C., Rasinhas A. C., de Almeida A. L. T., de Souza D. D. C., Paulino A. C., et al. Comparative analysis of liver involvement caused by two DENV-2 lineages using an immunocompetent murine model. Sci. Rep. 2021, 11(1), 9723, DOI: 10.1038/s41598-021-88502-2.
  41. Missbach-Guentner J., Pinkert-Leetsch D., Dullin C., Ufartes R., Hornung D., Tampe B., et al. 3D virtual histology of murine kidneys -high resolution visualization of pathological alterations by micro computed tomography. Sci. Rep. 2018, 8, 1407, DOI: 10.1038/s41598-018-19773-5.
  42. Sadeghinezhad J., Nyengaard J. R. Oxaliplatin Treatment for 3-Weeks Does not Affect Mice Kidney Structure: A Stereological Study. Iranian Journal of Veterinary Medicine. 2022, 16(2), 101—119, DOI: 10.22059/IJVM.2021.311503.1005132.
  43. Baldelomar E. J., Charlton J. R., Beeman S. C., Hann B. D., Cullen-McEwen L., Pearl V. M., et al. Phenotyping by magnetic resonance imaging nondestructively measures glomerular number and volume distribution in mice with and without nephron reduction. Kidney Int. 2016, 89(2), 498—505, DOI: 10.1038/ki.2015.316.
  44. Sato F., Tsuchihashi S., Kawashima N. Age changes in number and size of the murine renal glomeruli. Exp. Gerontol. 1975, 10, 325–331, DOI: 10.1016/0531-5565(75)90022-4.
  45. Pislyagin E. A., Manzhulo I. V., Dmitrenok P. S., Aminin D. L. Cucumarioside A2-2 causes changes in the morphology and proliferative activity in mouse spleen. Acta Histochem. 2016, 118(4), 387—392, DOI: 10.1016/j.acthis.2016.03.009.
  46. Meyer E. M., Schlake W., Grundmann E. Comparative histologic, histochemical, and histomorphometric studies of T and B cell areas in peripheral lymphoid organs of normal young adult BALB/C mice. Pathol. Res. Pract. 1979, 164(2), 141—156, DOI: 10.1016/s0344-0338(79)80019-9.
  47. Cherkasova M. N., Zhukhovitskii V. G., Borovaya T. G. Comparative Characteristics of the Spleen White Pulp in Experimental Models of Sepsis Caused by Different Strains of Pseudomonas aeruginosa. Bull. Exp. Biol. Med. 2020, 170(1), 46—48, DOI: 10.1007/s10517-020-05001-6.
  48. Harrison A. P., Erlwanger K. H., Elbrønd V. S., Andersen N. K., Unmack M. A. Gastrointestinal-tract models and techniques for use in safety pharmacology. J. Pharmacol. Toxicol. Methods. 2004, 49(3), 187—199, DOI: 10.1016/j.vascn.2004.02.008.
  49. Pusztaszeri M. P., Genta R. M., Cryer B. L. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nat. Clin. Pract Gastroenterol. Hepatol. 2007, 4, 442—453, DOI: 10.1038/ncpgasthep0896.
  50. Remmer H. The role of theliver in drug metabolism. Am. J. Med. 1970, 49(5), 617—629, DOI: 10.1016/s0002-9343(70)80129-2.
  51. Xu C., Li C. Y.-T., Kong A.-N. T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28(3), 249—268, DOI: 10.1007/BF02977789.
  52. Grant D. M. Detoxification pathways in the liver. J. Inherit. Metab. Dis. 1991, 14(4), 421—430, DOI: 10.1007/BF01797915.
  53. Apte U., Krishnamurthy P. Detoxification functions of the liver. In: Monga SPS, editor. Molecular pathology of liver diseases. Berlin: Springer; 2011. 147—463, DOI: 10.1007/978-1-4419-7107-4_11.
  54. You L. Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem. Biol. Interact. 2004, 147(3), 233—246, DOI: 10.1016/j.cbi.2004.01.006.
  55. Kleiner D. E. The histopathological evaluation of drug-induced liver injury. Histopathology. 2017, 70(1), 81—93, DOI: 10.1111/his.13082.
  56. Khairnar S. I., Kulkarni Y. A., Murugesan S., Singh K. Effects of Acute and Repeated Dose To­xicity Profiling of Chelidonic Acid in Rats: in Silico and in vivo Evidence. Chem. Biodivers. 2023, 20(12), e202301241, DOI: 10.1002/cbdv.202301241.
  57. Lohr J. W., Willsky G. R., Acara M. A. Renal drug metabolism. Pharmacol. Rev. 1998, 50(1), 107—141.
  58. Miners J. O., Yang X., Knights K. M., Zhang L. The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. Clin. Pharmacol. Ther. 2017, 102(3), 436—449, DOI: 10.1002/cpt.757.
  59. Knights K. M., Rowland A., Miners J. O. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol. 2013, 76(4), 587—602, DOI: 10.1111/bcp.12086.
  60. Radi Z. A. Kidney Pathophysiology, Toxicology, and Drug-Induced Injury in Drug Development. Int. J. Toxicol. 2019, 38(3), 215—227, DOI: 10.1177/1091581819831701.
  61. Kim S. Y., Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol. Ther. (Seoul). 2012, 20(3), 268—272, DOI: 10.4062/biomolther.2012.20.3.268.
  62. Fuchs T. C., Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. AAPS J. 2011, 13(4), 615—631, DOI: 10.1208/s12248-011-9301-x.
  63. Troth S. P., Simutis F., Friedman G. S., Todd S., Sistare F. D. Kidney Safety Assessment: Current Practices in Drug Development. Semin. Nephrol. 2019, 39(2), 120—131, DOI: 10.1016/j.semnephrol.2018.12.002.
  64. Griffin B. R., Faubel S., Edelstein C. L. Biomarkers of Drug-Induced Kidney Toxicity. Therapeutic Drug Monitoring. 2019, 41(2), 213—226, DOI: 10.1097/FTD.0000000000000589.
  65. Huang J. X., Blaskovich M. A., Cooper M. A. Cell- and biomarker-based assays for predicting nephrotoxicity. Expert Opin. Drug Metab. Toxicol. 2014, 10(12), 1621—1635, DOI: 10.1517/17425255.2014.967681.
  66. Nasibov T., Gorokhova A., Brazovsky K., Ryzhkova A., Porokhova E., Avdeeva E., et al. Potential Transmembrane Proteins-transporters of Chelidonic Acid for its Intracellular Uptake: In Silico Simulation. Pharm. Res. 2025, 42(10), 1749—1773, DOI: 10.1007/s11095-025-03934-z.
  67. Szabo L., Morey R., Palpant N. J., Wang P. L., Afari N., Jiang C., et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. Genome Biol. 2015, 16(1), 126, DOI: 10.1186/s13059-015-0690-5.
  68. Dai Y., Lee C.-H. Transport mechanism and structural pharmacology of human urate transporter URAT1. Cell Res. 2024, 34, 776—787, DOI: 10.1038/s41422-024-01023-1.
  69. Khairnar S. I., Kulkarni Y. A., Singh K. Mitigation of cisplatin-induced nephrotoxicity by chelidonic acid in Wistar rats. J. Trace Elem. Med. Biol. 2024, 81, 127321, DOI: j.jtemb.2023.127321.